Mickaël Le Douget - Concepedia

Author

Mickaël Le Douget

Also Known As

Mickael Le Douget, Mickaël Le Douget, Mickaël Le Douget

Publications

903

Citations

H-Index

Concepts

All Affiliations

Mickaël Le Douget is an author at Novartis (Switzerland) specializing in drug discovery, medicine, and pharmacology.

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	547
2	Natural Sciences	3	3	547
3	Biochemistry	3	3	547
4	Biomolecular Engineering	1	1	21
5	Chemical Biology	1	1	42

Mickaël Le Douget

Publications

899

Citations

H-Index

Page 1

	Year	Citations
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase Vito Guagnano, Pascal Furet, Carsten Spanka, Journal of Medicinal Chemistry Pharmaceutical ChemistryTumor BiologyMedicinal ChemistrySignaling PathwayGenitourinary Cancer	2011	484
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor Vito Guagnano, Audrey Kauffmann, Simon Wöhrle, Cancer Discovery	2012	352
The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition Pascal Furet, Vincent Bordas, Mickaël Le Douget, ChemMedChem Drug TargetYap-tead InteractionDirect CompetitionMolecular BiologyChemical Biology	2022	42
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors Holger Sellner, Emilie A. Chapeau, Pascal Furet, ChemMedChem Drug TargetNanotherapeuticsPeptide SciencePharmacotherapyPharmaceutical Chemistry	2023	21

Page 1